# Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine

> **NCT01407497** · PHASE1 · COMPLETED · sponsor: **Instituto Nacional de Saúde, Mozambique** · enrollment: 25 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** DNA HIVIS and MVA-CMDR
- **BIOLOGICAL:** DNA HIVIS and MVA-CMDR
- **BIOLOGICAL:** Saline solution
- **BIOLOGICAL:** Saline solution

## Key facts

- **NCT ID:** NCT01407497
- **Lead sponsor:** Instituto Nacional de Saúde, Mozambique
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-03
- **Final completion:** 2013-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01407497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01407497, "Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01407497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*